Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals

Article activity feed

1. 

   ScreenIT

   Jun 14, 2020

   SciScore for 10.1101/2020.06.12.20129460: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study protocol was approved by the Institutional Review Board of The Center Hospital of Shaoyang (V1. 0, 20200301), Hunan Province, China. Consent: Written informed consent was obtained from each participant.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Spike subunits S1- and S2-specific antibodies were detected by using horseradish peroxidase (HRP)-conjugated anti-human IgG and 3,3’,5,5’-tetramethylbenzidine substrate (Thermo Fisher Scientific, Waltham, MA, USA).	S2-specific suggested: None anti-human IgG s…

   SciScore for 10.1101/2020.06.12.20129460: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study protocol was approved by the Institutional Review Board of The Center Hospital of Shaoyang (V1. 0, 20200301), Hunan Province, China. Consent: Written informed consent was obtained from each participant.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Spike subunits S1- and S2-specific antibodies were detected by using horseradish peroxidase (HRP)-conjugated anti-human IgG and 3,3’,5,5’-tetramethylbenzidine substrate (Thermo Fisher Scientific, Waltham, MA, USA).	S2-specific suggested: None anti-human IgG suggested: None
   Healthy sera were used as negative controls, and monoclonal antibody specific for the receptor binding domain (RBD) of SARS-CoV-2 spike protein (anti-RBD/SARS-CoV-2; made in the lab, unpublished data) was used as positive control.	anti-RBD/SARS-CoV-2 suggested: None
   Of which, anti-dsDNA and anti-ANA antibodies were detected by ELISA (Zeus Scientific, Inc. New Jersey, USA), while anti-nucleosomes, histones, SmD1, U1-SnRNP, SS-A/Ro60KD, SS-A/Ro52 KD, SS-B/La, Sc1-70, CENP-B, Jo-1, and anti-PO/38KD were examined by Line Immuno Assay (LIA), according to the manufacturer’s protocols (HUMAN GmbH, Magdeburg, Germany).	anti-dsDNA suggested: None anti-ANA suggested: (MyBioSource Cat# MBS702259, RRID:AB_10889535) Jo-1 suggested: None anti-PO/38KD suggested: None
   The fluorescently labeled antibodies used in this study were BUV737 mouse anti-human CD4 (SK3) and PE mouse anti-human CXCR3 (1C6) (BD Biosciences), FITC mouse anti-human PD-1 (EH12.2H7) (BioLegend), and PE-eFluor 610 mouse anti-human CXCR5 (MU5UBEE) (Thermo Fisher Scientific, Waltham, MA, USA).	anti-human CD4 suggested: None anti-human CXCR3 suggested: None anti-human PD-1 suggested: None anti-human CXCR5 suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Naïve Huh7 cells were added to each well and incubated in 5% CO2 at 37°C for 24 hours.	Huh7 suggested: None
   Software and Algorithms
   Sentences	Resources
   The luminescence was measured, and the ID50 values were calculated with non-linear regression, i.e. log (inhibitor) vs. response (four parameters), using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA).	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)
   The fluorescently labeled antibodies used in this study were BUV737 mouse anti-human CD4 (SK3) and PE mouse anti-human CXCR3 (1C6) (BD Biosciences), FITC mouse anti-human PD-1 (EH12.2H7) (BioLegend), and PE-eFluor 610 mouse anti-human CXCR5 (MU5UBEE) (Thermo Fisher Scientific, Waltham, MA, USA).	BD Biosciences suggested: (BD Biosciences, RRID:SCR_013311)
   All data were analyzed with FlowJo 10.0 software (Tree Star, San Carlos, CA, USA).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   Analyses of the data were done by SPSS version 26 and GraphPad Prism version 8.0.	SPSS suggested: (SPSS, RRID:SCR_002865) GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. 

   Version published to 10.1101/2020.06.12.20129460v1 on medRxiv

   Jun 14, 2020